Mar 20, 2024

• Role of biomarker testing in optimal selection of first-line therapy for patients with non-small cell lung cancer (NSCLC) (0:00)
• Efficacy and safety with datopotamab deruxtecan for previously treated NSCLC (15:45)
• Antitumor activity with and current status of CEACAM5-targeted therapy for relapsed NSCLC (30:24)
• Evolution of drug development and clinical research (37:56)
• Key findings with sacituzumab govitecan for NSCLC (41:59)
• Telisotuzumab vedotin for patients with NSCLC and MET expression (48:44)
• Recent findings with tumor treating fields for metastatic NSCLC after disease progression on platinum-based therapy (50:49)
• Other novel antibody-drug conjugates under investigation for NSCLC (55:26)
• Case: A woman in her mid 50s with recurrent extensive-stage small cell lung cancer who developed pneumonitis on ifinatamab deruxtecan (59:05)
• Case: A woman in her early 60s with complete response to dose-reduced patritumab deruxtecan (1:00:15)